Virus-mimicking nanoparticles can stimulate long lasting immunity

Feb 23, 2011
Blue shows resting B cells. Red shows activated B cells that are being "trained" to produce high-quality antibodies. Green shows specialized antibody-producing cells. (Click image for high-resolution version. Credit: Emory University)

Emory postdoctoral fellow Sudhir Pai Kasturi, PhD, created tiny particles studded with molecules thatturn on Toll‑like receptors. He worked with colleague Niren Murthy, PhD, associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.

Vaccine scientists say their "Holy Grail" is to stimulate immunity that lasts for a lifetime. Live viral vaccines such as the smallpox or vaccines provide immune protection that lasts several decades, but despite their success, scientists have remained in the dark as to how they induce such long lasting immunity.

Scientists at the Emory Center have designed tiny nanoparticles that resemble viruses in size and immunological composition and that induce lifelong immunity in mice. They designed the particles to mimic the immune‑stimulating effects of one of the most successful vaccines ever developed – the yellow fever vaccine. The particles, made of biodegradable polymers, have components that activate two different parts of the innate and can be used interchangeablywith material from many different bacteria or viruses.

The results are described in this week’s issue of Nature.

“These results address a long‑standing puzzle in vaccinology: how do successful vaccines induce longlasting immunity?” says senior author Bali Pulendran, PhD, Charles Howard Candler professor of pathology and laboratory medicine at Emory University School of Medicine and a researcher at Yerkes National Primate Research Center.

“These particles could provide an instant way to stretch scarce supplies when access to viral material is limited, such as pandemic flu or during an emerging infection. In addition, there are many diseases, such as HIV, malaria, tuberculosis and dengue, that still lack effective vaccines, where we anticipate that this type of immunity enhancer could play a role.”

One injection of the live viral yellow fever vaccine, developed in the 1930s by Nobel Prize winner Max Theiler, can protect against disease‑causing forms of the virus for decades. Pulendran and his colleagues have been investigating how humans respond to the yellow fever vaccine, in the hopes of imitating it.

Several years ago, they established that the yellow fever vaccine stimulated multiple Toll‑like receptors (TLRs) in the innate immune system. TLRs are present in insects as well as mammals, birds and fish. They are expressed by cells that can sense bits of viruses, bacteria and parasites and can activate the immune system. Pulendran’s group demonstrated that the immune system sensed the yellow fever vaccine via multiple TLRs, and that this was required for the immunity induced by the vaccine.

“TLRs are like the sixth sense in our bodies, because they have an exquisite capacity to sense viruses and bacteria, and convey this information to stimulate the immune response,” Pulendran says. “We found that to get the best immune response, you need to hit more than one kind of Toll‑like receptor. Our aim was to create a synthetic particle that accomplishes this task.”

Emory postdoctoral fellow Sudhir Pai Kasturi, PhD, created studded with molecules thatturn on Toll‑like receptors. He worked with colleague Niren Murthy, PhD, associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.

“We are very excited about building on this platform to design improved vaccines for existing and emerging infectious diseases” says Kasturi, the primary author working in Pulendran’s lab at the Emory Vaccine Center. One of the particles’ components is MPL (monophosphoryl lipid A), a component of bacterial cell walls, and the other is imiquimod, a chemical that mimics the effects of viral RNA. The particles are made of PLGA—poly(lactic acid)‑co‑(glycolic acid)—a synthetic polymer used for biodegradable grafts and sutures.

All three components are FDA‑approved for human use individually. For several decades, the only FDA‑approved vaccine additive was alum, until a cervical cancer vaccine containing MPL was approved in 2009. Because of immune system differences between mice and monkeys, the scientists replaced imiquimod with the related chemical resiquimod for monkey experiments.

In mice, the particles can stimulate production of antibodies to proteins from flu virus or anthrax bacteria several orders of magnitude more effectively than alum, the authors found. In addition, the immune cells persist in lymph nodes for at least 18months, almost the lifetime of a mouse. In experiments with monkeys, nanoparticles with viral protein could induce robust responses greater than five times the response induced by a dose of the same viral protein given by itself, without the nanoparticles.

Explore further: Gold nanorods target cancer cells

More information: S.P. Kasturi et al. Programming the magnitude and persistence of antibody responses with innateimmunity. Nature (2011). doi:10.1038/nature09737

Related Stories

Nano-sized vaccines

Feb 22, 2011

MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

New West Nile and Japanese encephalitis vaccines produced

May 30, 2008

University of Texas Medical Branch at Galveston researchers have developed new vaccines to protect against West Nile and Japanese encephalitis viruses. The investigators created the vaccines using an innovative technique ...

Novel pandemic flu vaccine effective against H5N1 in mice

Mar 01, 2009

Vaccines against H5N1 influenza will be critical in countering a possible future pandemic. Yet public health experts agree that the current method of growing seasonal influenza vaccines in chicken eggs is slow and inefficient.

Vitamin A signals offer clues to treating autoimmunity

Mar 01, 2009

Distributed around the body, dendritic cells act as the security alarms of the immune system. After sensing the presence of intruders, dendritic cells can transmit the alarm to white blood cells or tell them to relax, depending ...

Recommended for you

Gold nanorods target cancer cells

Dec 18, 2014

Using tiny gold nanorods, researchers at Swinburne University of Technology have demonstrated a potential breakthrough in cancer therapy.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.